AstraZeneca PLC AZN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 07/12/24 EDT

79.19

-0.05 (-0.06%)

Volume

45,365

79.24

+1.30 (+1.67%)

Volume

2,982,788

52 week range

60.47 - 80.86

Open79.52
Day High79.79
Day Low79.18
Prev Close77.94
52 Week High80.86
52 Week High Date06/06/24
52 Week Low60.47
52 Week Low Date02/12/24

Key Stats

Market Cap245.686B
Shares Out3.10B
10 Day Average Volume2.92M
Dividend1.45
Dividend Yield1.83%
Beta0.47
YTD % Change17.65

KEY STATS

Open79.52
Day High79.79
Day Low79.18
Prev Close77.94
52 Week High80.86
52 Week High Date06/06/24
52 Week Low60.47
52 Week Low Date02/12/24
Market Cap245.686B
Shares Out3.10B
10 Day Average Volume2.92M
Dividend1.45
Dividend Yield1.83%
Beta0.47
YTD % Change17.65

RATIOS/PROFITABILITY

EPS (TTM)2.03
P/E (TTM)39.08
Fwd P/E (NTM)16.35
EBITDA (TTM)14.487B
ROE (TTM)17.29%
Revenue (TTM)47.611B
Gross Margin (TTM)82.17%
Net Margin (TTM)13.31%
Debt To Equity (MRQ)92.27%

EVENTS

Earnings Date07/25/2024(est)
Ex Div Date02/22/2024
Div Amount0.985
Split Date-
Split Factor-

Latest On AstraZeneca PLC

June Monthly Meeting: Jim Cramer reveals his outlook for stocks in the second half of 2024June 27, 2024CNBC.com
How to invest $100,000 with stocks at all-time highs? What 2 wealth managers sayJune 16, 2024CNBC.com

Content From Our Affiliates

Is AstraZeneca Stock (NASDAQ:AZN) Overbought or Worth the Valuation?July 11, 2024TipRanks
AstraZeneca price target lowered to 13,100 GBp from 13,400 GBp at GuggenheimJuly 11, 2024TipRanks
AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at BarclaysJuly 10, 2024TipRanks
Deutsche Numis Reaffirms Their Hold Rating on AstraZeneca (AZN)July 10, 2024TipRanks
J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)July 10, 2024TipRanks

Profile

AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases...

Michel Demare

Non-Executive Independent Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Aradhana Sarin M.D.

Chief Financial Officer, Executive Director

Ruud Dobber Ph.D.

Executive Vice President - BioPharmaceuticals Business Unit

Susan Galbraith

Executive Vice President - Oncology and Research and Development

Address

Cambridge Biomedical Campus

Cambridge

CB2 0AA

United Kingdom

https://www.astrazeneca.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
NVS Novartis AG	111.70	+1.20	+1.09%
ABBV AbbVie Inc	170.28	+0.37	+0.22%
RHHBY Roche Holding AG	35.69	+0.53	+1.51%
PFE Pfizer Inc	28.92	+0.26	+0.91%
MRK Merck & Co Inc	127.76	-1.21	-0.94%